Chapter 1 Microbiome Therapeutics Market: Methodology And Scope
1.1 Research Methodology
1.2 Research Assumptions
1.2.1 Estimates and forecast timeline
1.3 Information Procurement
1.3.1 Purchased database
1.3.2 GVR’s internal database
1.3.3 Secondary sources
1.3.4 Primary research
1.3.5 Details of primary research
1.4 Information or Data Analysis
1.4.1 Data analysis models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity flow analysis
1.6.1.1 Approach 1: Commodity flow approach
1.6.2 Volume price analysis (model 2)
1.6.2.1 Approach 2: Volume price analysis
1.6.2.2 Revenue modeling
1.7 List of Secondary Sources
1.8 List of Primary Sources
Chapter 2 Microbiome Therapeutics Market: Executive Summary
2.1 Market summary
Chapter 3 Microbiome Therapeutics Market: Industry Outlook
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Market Dynamics
3.3.1 Market Driver Analysis
3.3.1.1 Increasing number of strategic collaborations
3.3.1.2 Rise in prevalence of target diseases
3.3.1.3 Advancements in microbiome technology to develop novel products
3.3.1.4 Increasing R&D in order to understand the human microbiome
3.3.2 Market Restraint Analysis
3.3.2.1 Stringent regulatory guidelines
3.3.2.2 High cost of development, and production
3.4 Porter’s Five Forces Analysis
3.5 SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
3.6 Regulatory Framework
3.7 User Perspective Analysis
Chapter 4 Microbiome Therapeutics Market: Competitive Landscape
4.1 Recent developments & impact analysis, by key market participants
4.1.1 Ansoff Matrix
4.2 Major deals & strategic alliances analysis
4.2.1 Joint Ventures
4.2.2 Licensing and Partnerships
4.2.3 Technological Collaborations
4.3 Company/Competition Categorization
4.4 Vendor Landscape
4.4.1 List Of Key Distributors and Channel Partners
4.4.2 Key Customers
4.5 Public Companies
4.5.1 Company Market Position Analysis
4.6 Private Companies
4.6.1 List Of Key Emerging Companies
4.6.2 Regional Network Map
Chapter 6 Microbiome Therapeutics Market: Type Business Analysis
5.1 Definition and Scope
5.2 Type Market Share Analysis, 2021 & 2030
5.3 Global Microbiome Therapeutics Market, By Type, 2018 To 2030
5.4 Market Size & Forecasts and Trend Analyses, 2018 to 2030
5.4.1 FMT
5.4.1.1 FMT Market 2018 - 2030 (USD Million)
5.4.2 Microbiome Drugs
5.4.2.1 Microbiome Drugs Market, 2018 - 2030 (USD Million)
Chapter 6 Microbiome Therapeutics Market: Application Business Analysis
6.1 Definition and Scope
6.2 Application Market Share Analysis, 2021 & 2030
6.3 Global Microbiome Therapeutics Market, By Application, 2018 To 2030
6.4 Market Size & Forecasts and Trend Analyses, 2018 to 2030
6.4.1 C. difficile
6.4.1.1 C. difficile Market 2018 - 2030 (USD Million)
6.4.2 Cohn's Disease
6.4.2.1 Cohn's Disease Market, 2018 - 2030 (USD Million)
6.4.3 Inflammatory Bowel Disease
6.4.3.1 Inflammatory Bowel Disease Market, 2018 - 2030 (USD Million)
6.4.4 Diabetes
6.4.4.1 Diabetes Market, 2018 - 2030 (USD Million)
6.4.5 Others
6.4.5.1 Others Market, 2018 - 2030 (USD Million)
Chapter 7 Microbiome Therapeutics Market: Regional Business Analysis
7.1 Definition & Scope
7.2 Regional Market Share Analysis, 2021 & 2030
7.3 Regional Market Dashboard
7.4 Regional Market Snapshot
7.5 SWOT Analysis, By Factor (Political & Legal, Economic And Technological)
7.5.1 North America
7.5.2 Europe
7.5.3 Asia Pacific
7.5.4 Latin America
7.5.5 MEA
7.6 Market Size, & Forecasts, Trend Analysis, 2021 to 2030
7.7 North America
7.7.1 North America Microbiome Therapeutics Market, 2018 - 2030 (USD Million)
7.7.2 U.S.
7.7.2.1 U.S. Microbiome Therapeutics Market, 2018 - 2030 (USD Million)
7.7.3 Canada
7.7.3.1 Canada Microbiome Therapeutics Market, 2018 - 2030 (USD Million)
7.8 Europe
7.8.1 Europe Microbiome Therapeutics Market, 2018 - 2030 (USD Million)
7.8.2 U.K.
7.8.2.1 U.K. Microbiome Therapeutics Market, 2018 - 2030 (USD Million)
7.8.3 Germany
7.8.3.1 Germany Microbiome Therapeutics Market, 2018 - 2030 (USD Million)
7.8.4 France
7.8.4.1 France Microbiome Therapeutics Market, 2018 - 2030 (USD Million)
7.8.5 Italy
7.8.5.1 Italy Microbiome Therapeutics Market, 2018 - 2030 (USD Million)
7.8.6 Spain
7.8.6.1 Spain Microbiome Therapeutics Market, 2018 - 2030 (USD Million)
7.9 Asia Pacific
7.9.1 Asia-Pacific Microbiome Therapeutics Market, 2018 - 2030 (USD Million)
7.9.2 Japan
7.9.2.1 Japan Microbiome Therapeutics Market, 2018 - 2030 (USD Million)
7.9.3 China
7.9.3.1 China Microbiome Therapeutics Market, 2018 - 2030 (USD Million)
7.9.4 India
7.9.4.1 India Microbiome Therapeutics Market, 2018 - 2030 (USD Million)
7.8.4 Australia
7.8.4.1 Australia Microbiome Therapeutics Market, 2018 - 2030 (USD Million)
7.8.5 South Korea
7.8.5.1 South Korea Microbiome Therapeutics Market, 2018 - 2030 (USD Million)
7.10 Latin America
7.10.1 Latin America Microbiome Therapeutics Market Market, 2018 - 2030 (USD Million)
7.10.2 Brazil
7.10.2.1 Brazil Microbiome Therapeutics Market, 2018 - 2030 (USD Million)
7.10.3 Mexico
7.10.3.1 Mexico Microbiome Therapeutics Market, 2018 - 2030 (USD Million)
7.8.3 Argentina
7.8.3.1 Argentina Microbiome Therapeutics Market, 2018 - 2030 (USD Million)
7.11 MEA
7.11.1 MEA Microbiome Therapeutics Market, 2018 - 2030 (USD Million)
7.11.2 South Africa
7.11.2.1 South Africa Microbiome Therapeutics Market, 2018 - 2030 (USD Million)
7.11.2 Saudi Arabia
7.11.2.1 Saudi Arabia Microbiome Therapeutics Market, 2018 - 2030 (USD Million)
7.11.3 UAE
7.11.3.1 Uae Microbiome Therapeutics Market, 2018 - 2030 (USD Million)
Chapter 8 Microbiome Therapeutics Market: Company Profiling
8.1 Company Profiles
8.1.1. OpenBiome
8.1.1.1 Company overview
8.1.1.2 Financial Performance
8.1.1.3 Product benchmarking
8.1.1.4 Strategic initiatives
8.1.2. Seres Therapeutics Inc.
8.1.2.1 Company overview
8.1.2.2 Financial Performance
8.1.2.3 Product benchmarking
8.1.2.4 Strategic initiatives
8.1.3. 4D Pharma plc.
8.1.3.1 Company overview
8.1.3.2 Financial Performance
8.1.3.3 Product benchmarking
8.1.3.4 Strategic initiatives
8.1.4. Locus Biosciences, Inc.
8.1.4.1 Company overview
8.1.4.2 Financial Performance
8.1.4.3 Product benchmarking
8.1.4.4 Strategic initiatives
8.1.5. Enterome SA
8.1.5.1 Company overview
8.1.5.2 Financial Performance
8.1.5.3 Product benchmarking
8.1.5.4 Strategic initiatives
8.1.6. Finch Therapeutics Group, Inc.
8.1.6.1 Company overview
8.1.6.2 Financial Performance
8.1.6.3 Product benchmarking
8.1.6.4 Strategic initiatives
8.1.7. Intralytix, Inc.
8.1.7.1 Company overview
8.1.7.2 Financial Performance
8.1.7.3 Product benchmarking
8.1.7.4 Strategic initiatives
8.1.8. Microbiotica
8.1.8.1 Company overview
8.1.8.2 Financial Performance
8.1.8.3 Product benchmarking
8.1.8.4 Strategic initiatives
8.1.9. Second Genome
8.1.9.1 Company overview
8.1.9.2 Financial Performance
8.1.9.3 Product benchmarking
8.1.9.4 Strategic initiatives
8.1.10. Rebiotix Inc.
8.1.10.1 Company overview
8.1.10.2 Financial Performance
8.1.10.3 Product benchmarking
8.1.10.4 Strategic initiatives
8.1.11. Vedanta Bioscience, Inc.
8.1.11.1 Company overview
8.1.11.2 Financial Performance
8.1.11.3 Product benchmarking
8.1.11.4 Strategic initiatives
